CLOs on the Move

Insys

www.insysrx.com

 
Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.insysrx.com
  • 1333 South Spectrum Boulevard Suite 100
    Chandler, AZ USA 85286
  • Phone: 602.910.2617

Executives

Name Title Contact Details
Sanga Emmanuel
 VP - Chief Compliance Officer Profile
Mollie Roth
 Director of Compliance Profile
Mark Nance
 Chief Legal Officer and General Counsel Profile
Mark Nance
 Chief Legal Officer and General Counsel Profile

Similar Companies

Zura Bio Limited

Zura Bio is a clinical stage biotechnology company focused on developing ZB 168, an anti IL7Rα inhibitor, for the treatment of alopecia areata and other inflammatory diseases.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Agadia

Agadia is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MBC Pharma (Main)

MBC Pharma (Main) is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spectrum Plastics Group

We are leaders in medical plastics design, development & manufacture, with over 2,000 employees, and 20 manufacturing locations worldwide.